logo
logo
Sign in

Treatment Resistant Depression Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Depression

avatar
Anjali CMI
Treatment Resistant Depression Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Depression

The global Treatment Resistant Depression Market is estimated to be valued at US$ 1,180.0 Mn in 2022 and is expected to exhibit a CAGR of 3.4% over the forecast period 2022 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:

The Treatment Resistant Depression Market refers to the market for drugs and therapies that are specifically developed to treat patients suffering from depression that does not respond to traditional antidepressant treatments. The market offers various products and treatments, including psychotherapy, electroconvulsive therapy, and alternative medicines. It addresses the increasing need for more effective and personalized treatments for individuals who do not show improvement with standard antidepressant medications.


Market Key Trends:

One key trend observed in the Treatment Resistant Depression Market is the growing demand for novel therapeutics with different mechanisms of action. Traditional antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), have limitations in treating treatment-resistant depression. As a result, pharmaceutical companies are focusing on developing innovative drugs targeting alternative pathways and utilizing different mechanisms to effectively treat depression. These novel therapeutics offer new hope for patients who have not responded to traditional treatments and present significant growth opportunities in the market.


Key players in the Treatment Resistant Depression Market include AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd.


PEST Analysis:


Political: The political factors affecting the treatment resistant depression market include government regulations and policies related to pharmaceuticals and mental health. These regulations can impact the availability and pricing of treatments, as well as the approval process for new drugs.


Economic: Economic factors influence the affordability and accessibility of treatment options for depression. Factors such as healthcare expenditure, insurance coverage, and the overall economic conditions of a country can impact the market's growth.


Social: Social factors play a significant role in the treatment resistant depression market. Increasing awareness and acceptance of mental health issues in society drive the demand for effective treatments. Social stigma related to mental illnesses and the availability of support systems also influence the market.


Technological: Technological advancements in the field of mental health research and treatment contribute to the growth of the treatment resistant depression market. Innovations in pharmacology and therapies, including the development of new antidepressant drugs and non-invasive brain stimulation techniques, have a positive impact on the market.


Key Takeaways:


The global Treatment Resistant Depression Market Demand is expected to witness high growth, exhibiting a CAGR of 3.4% over the forecast period from 2022 to 2030. This growth can be attributed to the increasing prevalence of treatment-resistant depression, as well as the growing focus on mental health awareness and treatment.


In terms of regional analysis, North America is the fastest growing and dominating region in the treatment resistant depression market. The region's strong healthcare infrastructure and high awareness about mental health contribute to this growth. Additionally, the presence of key market players in North America further drives the market's expansion in the region.


Key players operating in the treatment resistant depression market include AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd. These companies play a crucial role in the development and commercialization of treatment options for resistant depression.


Read more @ https://www.newsstatix.com/treatment-resistant-depression-market-emerging-therapies-and-key-players/

collect
0
avatar
Anjali CMI
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more